Home›Companies›Biotech & Pharma›Akelos

Akelos, Inc.

Develops non-opioid drug candidates for people with neuropathic pain.

Updated Nov 10, 2026·Latest SEC filing Mar 16, 2026·Suggest an edit

About Akelos

Akelos is a private company based in New York, New York. It has reported $1,811,500 raised in four offerings on Form D since November 2018.

Funding Rounds (SEC Form D)

First saleFiled with SECAmount soldInvestorsAvg. checkTermsFiling
Mar 9, 2026Mar 16, 2026$1,486,000target not set81$18,346Equity, Debt, OptionsRule 506(c)Form D ↗
Oct 21, 2022Oct 28, 2022$5,500of $14.0M target1$5,500EquityRule 506(c)Form D ↗
Jan 31, 2019Feb 5, 2019$25,000of $3.0M target1$25,000EquityRule 506(b)Form D ↗
Oct 23, 2018Nov 28, 2018$295,000fully sold12$24,583EquityRule 506(b)Form D ↗
Total, four offerings$1,811,500

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Leadership Team

Executive officers and directors listed on Akelos's Form D filed Mar 16, 2026.

SF
Steven Fox
Founder

Sources

  1. SECAkelos, Inc. filing history